Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:50 pm Sale |
2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX |
PERCEPTIVE ADVISORS LLC | 0 0.000% |
-4,776,306 (Position Closed) |
Filing History |
| 2024-06-03 5:56 pm Sale |
2024-05-30 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 0 0.000% |
-7,150,826 (Position Closed) |
Filing History |
| 2024-02-14 5:09 pm Sale |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Kayyem Jon Faiz | 3,308,123 7.000% |
-97,686 (-2.87%) |
Filing History |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 4,724,352 9.990% |
870,485 (+22.59%) |
Filing History |
| 2024-02-14 4:51 pm Purchase |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
PERCEPTIVE ADVISORS LLC | 4,776,306 9.900% |
1,462,523 (+44.13%) |
Filing History |
| 2024-02-14 4:16 pm Purchase |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Mark Lappe | 3,184,508 6.700% |
34,794 (+1.10%) |
Filing History |
| 2024-02-14 4:12 pm Sale |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Eckelman Brendan P. | 2,397,219 5.100% |
-352,734 (-12.83%) |
Filing History |
| 2024-02-14 10:00 am Purchase |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 7,150,826 15.100% |
511,627 (+7.71%) |
Filing History |
| 2024-01-29 5:25 pm Purchase |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
BLACKROCK INC BLK |
2,715,672 5.700% |
299,484 (+12.39%) |
Filing History |
| 2024-01-23 10:10 am Sale |
2023-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
STATE STREET CORP STT |
1,635,726 3.460% |
-871,262 (-34.75%) |
Filing History |
| 2023-03-08 6:00 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Inhibrx Inc. INBX |
3,147,235 7.200% |
650,849 (+26.07%) |
Filing History |
| 2023-03-08 6:00 pm Sale |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Inhibrx Inc. INBX |
2,496,386 5.700% |
-810,924 (-24.52%) |
Filing History |
| 2023-03-08 5:59 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
Inhibrx Inc. INBX |
3,307,310 7.600% |
995,855 (+43.08%) |
Filing History |
| 2023-02-14 4:45 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 3,853,867 8.900% |
668,036 (+20.97%) |
Filing History |
| 2023-02-14 2:35 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
PERCEPTIVE ADVISORS LLC | 3,313,783 7.600% |
1,345,039 (+68.32%) |
Filing History |
| 2023-02-14 1:18 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
VIKING GLOBAL INVESTORS LP | 6,639,199 15.200% |
1,333,333 (+25.13%) |
Filing History |
| 2023-02-08 2:02 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
STATE STREET CORP STT |
2,506,988 5.760% |
2,506,988 (New Position) |
Filing History |
| 2023-02-03 12:10 pm Purchase |
2022-12-31 | 13G | Inhibrx Biosciences, Inc. INBX |
BLACKROCK INC BLK |
2,416,188 5.500% |
2,416,188 (New Position) |
Filing History |
| 2022-10-17 5:21 pm Purchase |
2022-10-07 | 13G | Inhibrx Biosciences, Inc. INBX |
RA Capital Management, L.P. | 3,185,831 8.160% |
3,185,831 (New Position) |
Filing History |
| 2022-07-18 8:59 pm Purchase |
2022-07-05 | 13G | Inhibrx Biosciences, Inc. INBX |
PERCEPTIVE ADVISORS LLC | 1,968,744 5.000% |
1,968,744 (New Position) |
Filing History |